Last checked at 18 Jun 2020 12:05
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Result of General Meeting and grant of warrants
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that at its general meeting held earlier today, all resolutions were duly passed. The results of the proxy voting for the resolutions are set out below.
Resolution | Votes For* | % of votes cast** | Votes Against | % of votes cast** | Total votes cast** | Votes withheld** | % of issued share capital voted** |
1. To authorise the Directors to allot securities. | 34,120,538
| 99.988 | 4,147 | 0.0122 | 34,124,685
| 0 | 22.422 |
2. To disapply statutory pre-emption rights***. | 34,115,738
| 99.985 | 5,200 | 0.0152 | 34,120,938 | 3,747 | 22.419 |
*Votes "For" include votes giving the Chairman discretion.
** A 'Vote Withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.
*** Proposed as a special resolution.
Following the approval of shareholders at today's general meeting, and further to the announcement on 1 June 2020, the Company has now granted warrants over 2,536,562 new ordinary shares to its brokers in respect of the Placing, as announced on 13 May 2020. The warrants are exercisable at a price of 4p until 20 May 2022.
Following this grant, the Company has a total of 2,536,562 warrants over ordinary shares outstanding, which represents 1.67 per cent. of the Company's issued share capital as at the date of this announcement.
Defined terms within this announcement shall have the meaning as set out in the announcement of 1 June 2020 unless otherwise defined herein.
Enquiries:
N4 Pharma Plc Nigel Theobald, CEO
|
Via Scott PR |
Allenby Capital Limited James Reeve/Asha Chotai
| Tel: +44(0)203 328 5656 |
Scott PR Georgia Smith
| Tel: +44(0)1477 539 539 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.